Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference
Daré Bioscience (NASDAQ: DARE) announces participation of President and CEO Sabrina Martucci Johnson at the 2022 Virtual Growth Conference hosted by Maxim Group LLC and M-Vest from March 28-30, 2022. Johnson will join the panel titled “Advances in Women's Health: From Clinical to Commercial” on March 28 at 3:00 p.m. ET and deliver a company presentation available on-demand from March 28 at 9:00 a.m. ET. Archived webcasts will be accessible from April 4-8, 2022, and registration links for the conference and presentations are provided in the PR.
- None.
- None.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, being held March 28-30, 2022.
Ms. Johnson will participate in the panel entitled “Advances in Women's Health: From Clinical to Commercial” on Monday, March 28, 2022, at 3:00 p.m. ET. Ms. Johnson will also provide a company presentation, available on-demand beginning on March 28, 2022, at 9:00 a.m. ET.
The panel and the company presentation will be hosted on Maxim’s M-Vest website and available to those registered for the conference. Interested parties can register for the conference and access the live webcast of the panel and the on-demand company presentation via the links below:
Panel webcast link: https://m-vest.com/events/2022-virtual-growth-conference
Presentation webcast link: https://m-vest.com/events/2022-virtual-growth-conference/p/dare
An archived webcast of the Advances in Women’s Health panel will be available from April 4 – 8, 2022, under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.
About Daré Bioscience
Daré Bioscience is a biopharmaceutical company committed to advancing innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health.
Daré’s first FDA-approved product, XACIATO™ (clindamycin phosphate), is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Daré’s product portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream,
Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Lisa Walters-Hoffert, Chief Financial Officer
Daré Bioscience, Inc.
lwalters@darebioscience.com
858.926.7655
Investor Relations
Lee Roth, Sr. Vice President
Burns McClellan
Lroth@burnsmc.com
+1 212.213.0006
OR
Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Canale Communications
jake.robison@canalecomm.com
619.849.5383
Source: Daré Bioscience, Inc.
FAQ
What event will Daré Bioscience participate in on March 28, 2022?
Who is representing Daré Bioscience at the Virtual Growth Conference?
What is the focus of the panel session at the conference?
When will the on-demand company presentation be available?
When can attendees access the archived webcast of the panel?
